When should low‑dose aspirin be started in adults aged 40‑70 years with a coronary artery calcium score greater than 100 and no prior atherosclerotic cardiovascular disease or high bleeding‑risk factors?

Aspirin Indication in Patients with High Coronary Calcium Score

In adults aged 40–70 years with a coronary artery calcium (CAC) score >100 and no prior atherosclerotic cardiovascular disease or high bleeding-risk factors, low-dose aspirin (75–100 mg daily) should be considered after shared decision-making, as this threshold identifies individuals in whom cardiovascular benefit outweighs bleeding risk. 1, 2

CAC-Guided Aspirin Decision Algorithm

CAC ≥100: Consider Aspirin

• Multiple international guideline bodies—including the ACC/AHA, Society of Cardiovascular Computed Tomography (SCCT), National Lipid Association (NLA), Cardiac Society of Australia and New Zealand (CSANZ), and Chinese cardiovascular societies—explicitly endorse CAC ≥100 as the threshold at which aspirin's cardiovascular benefit exceeds bleeding risk. 1, 2
• For patients with CAC ≥100, the estimated 5-year number needed to treat (NNT) is 140 to prevent one cardiovascular event, compared to a number needed to harm (NNH) of 518 for major bleeding—demonstrating net benefit. 3
• For CAC >400, the net clinical benefit is even greater; aspirin improves outcomes regardless of traditional risk-factor levels. 1, 2

CAC = 0: Do Not Use Aspirin

• When CAC = 0, aspirin is not recommended even if calculated ASCVD risk is moderate, because bleeding risk outweighs any cardiovascular benefit. 1, 2
• The estimated 5-year NNT for CAC = 0 is 1,190 versus NNH of 567, indicating net harm. 3
• The only rare exception is CAC = 0 combined with >20% 10-year ASCVD risk, where aspirin may be considered. 1

CAC 1–99: Generally Not Recommended

• Evidence is mixed for this intermediate range; aspirin is generally not recommended unless multiple additional high-risk features are present (current smoking, strong family history of premature ASCVD, markedly elevated lipoprotein(a), chronic kidney disease with albuminuria). 2

Age-Specific Restrictions

Ages 40–70 Years: Eligible Population

• Low-dose aspirin may be considered only in this age range when CAC ≥100 and bleeding risk is low. 1
• The 2019 ACC/AHA guideline provides a Class IIb recommendation (may be considered) for adults 40–70 years at higher ASCVD risk without increased bleeding risk. 1, 2

Age >70 Years: Do Not Initiate

• Aspirin should not be started for primary prevention in individuals >70 years, irrespective of ASCVD risk or CAC score, because bleeding risk outweighs cardiovascular benefit. 1, 2
• The ASPREE trial demonstrated increased bleeding and mortality without cardiovascular benefit in this age group, with extended follow-up showing higher major adverse cardiovascular events (HR 1.17) and persistent bleeding risk (HR 1.24). 1, 2

Age <40 Years: Insufficient Evidence

• Aspirin should not be initiated for primary prevention in individuals <40 years due to insufficient evidence of benefit. 2

Absolute Contraindications (Do Not Use Aspirin)

• Prior gastrointestinal bleeding or active peptic ulcer disease 2, 4
• Known bleeding disorder or thrombocytopenia 2, 4
• Severe liver disease 2, 4
• Concurrent anticoagulation (warfarin or DOACs) 2, 4
• Regular NSAID use 2, 4
• Uncontrolled hypertension 2, 4
• Chronic kidney disease (increases bleeding risk) 2
• Age >70 years 1, 2

Shared Decision-Making Framework

Benefits to Discuss

• Approximately 12% relative reduction in cardiovascular events, driven mainly by fewer non-fatal myocardial infarctions. 2, 5
• Minimal effect on cardiovascular mortality (relative risk ≈0.95). 5

Harms to Discuss

• Approximately 29% relative increase in major bleeding (predominantly gastrointestinal), translating to roughly 5 major bleeds per 1,000 persons per year. 2, 5
• In real-world settings, treating 100 patients for 5–10 years prevents roughly one cardiovascular event while causing roughly one major bleeding event. 2, 5

Practical Dosing Recommendations

• Use low-dose aspirin 75–100 mg daily (81 mg is the standard U.S. tablet). 2, 6
• No evidence supports doses >162 mg for primary prevention; higher doses increase bleeding risk without additional cardiovascular benefit. 2, 6
• The ADAPTABLE trial demonstrated no significant differences in cardiovascular events or major bleeding between 81 mg and 325 mg daily doses. 6, 7

Why CAC Outperforms Traditional Risk Scores

• The pooled cohort equations (PCE) tend to overestimate actual ASCVD risk in contemporary populations receiving optimal statin and blood-pressure therapy. 2, 8
• CAC directly visualizes coronary plaque burden, providing more accurate risk stratification than PCE-derived estimates, especially when traditional risk factors are well-controlled. 1, 8
• Higher CAC categories are associated with both ASCVD and bleeding events, but the association with ASCVD is stronger and persists after multivariable adjustment. 9

Common Clinical Pitfalls to Avoid

• Do not prescribe aspirin automatically based solely on a 10% 10-year ASCVD risk threshold; without CAC stratification, the benefit-to-harm balance is unfavorable. 2, 3
• Do not rely on traditional risk scores alone when CAC testing is available; CAC ≥100 identifies a subgroup with net benefit that would be missed by risk scores alone. 1, 3
• Do not continue aspirin in patients who age beyond 70 years without documented ASCVD; reassess bleeding risk regularly. 2, 5
• Gastrointestinal bleeding risk in real-world settings may be as high as 5 per 1,000 person-years; this risk must be incorporated into net-benefit calculations. 2, 5

Context: The Paradigm Shift in Aspirin Use

• The 2019 ACC/AHA guideline downgraded aspirin to a Class IIb recommendation (may be considered) for primary prevention, reflecting a shift based on three landmark 2018 trials (ASCEND, ARRIVE, ASPREE) that together enrolled >46,000 participants and demonstrated that modest cardiovascular benefit was offset by increased bleeding risk. 2
• Modern populations have lower smoking rates, widespread statin use (34–75% in recent trials versus minimal use in older studies), and improved blood-pressure control; these factors lower baseline cardiovascular risk, making aspirin's absolute benefit smaller while bleeding risk remains unchanged. 1, 2, 5
• In unselected populations, the number needed to treat to cause a major bleed (210) is lower than the number needed to treat to prevent an ASCVD event (265), indicating net harm. 2